{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Tumor&page=65",
    "query": {
      "condition": "Germ Cell Tumor",
      "page": 65
    },
    "page_size": 10
  },
  "pagination": {
    "page": 65,
    "page_size": 10,
    "total_count": 5233,
    "total_pages": 524,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Tumor&page=66&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Germ+Cell+Tumor&page=64&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T18:26:15.508Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02263898",
      "title": "Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "Raf kinase inhibitor LGX818",
          "type": "DRUG"
        },
        {
          "name": "binimetinib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-01",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2020-07-27",
      "last_synced_at": "2026-10-31T18:26:15.508Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02263898"
    },
    {
      "nct_id": "NCT06910306",
      "title": "Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Recurrent Glioblastoma",
        "Recurrent Gliomas"
      ],
      "interventions": [
        {
          "name": "Device :DaRT seeds",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Alpha Tau Medical LTD.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-10-01",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-10-31T18:26:15.508Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • New York, New York • Columbus, Ohio",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06910306"
    },
    {
      "nct_id": "NCT00880308",
      "title": "Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor Cancers",
        "Medulloblastoma",
        "Basal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "LDE225",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2009-03",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-10-31T18:26:15.508Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • San Antonio, Texas",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00880308"
    },
    {
      "nct_id": "NCT03708328",
      "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Metastatic Melanoma",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Small Cell Lung Cancer (SCLC)",
        "Esophageal Squamous Cell Carcinoma (ESCC)"
      ],
      "interventions": [
        {
          "name": "Lomvastomig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2018-10-15",
      "completion_date": "2024-07-09",
      "has_results": true,
      "last_update_posted_date": "2025-08-20",
      "last_synced_at": "2026-10-31T18:26:15.508Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03708328"
    },
    {
      "nct_id": "NCT07636200",
      "title": "The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Advanced Solid Tumor Cancer",
        "Stage IV Cancer (Solid Tumors Only)",
        "Glioblastoma",
        "Stage III Ovarian Cancer",
        "Small Cell Lung Cancer Extensive Stage"
      ],
      "interventions": [
        {
          "name": "Written Exposure-Based Coping Intervention (EASE)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care Control Condition",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Colorado, Boulder",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2026-05-04",
      "completion_date": "2030-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-31T18:26:15.508Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Boulder, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07636200"
    },
    {
      "nct_id": "NCT04349436",
      "title": "Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma",
        "Basal Cell Carcinoma",
        "Locally Advanced Cutaneous Squamous Cell Carcinoma",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "RP1, intra-tumoral injection, oncolytic virus",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Replimune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2020-05-15",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-10-31T18:26:15.508Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04349436"
    },
    {
      "nct_id": "NCT04197934",
      "title": "WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Astrocytoma, IDH-Wildtype",
        "Glioblastoma, IDH-Wildtype",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Neoplasm in the Central Nervous System",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection - blood samples",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection - CSF samples",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "EGFR/EGFRvIII Inhibitor WSD0922-FU",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2019-12-20",
      "completion_date": "2031-02-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-31T18:26:15.508Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197934"
    },
    {
      "nct_id": "NCT02076906",
      "title": "MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Pediatric Solid Tumors",
        "Refractory Pediatric Solid Tumors",
        "Rhabdomyosarcoma",
        "Ewing Sarcoma",
        "Osteosarcoma",
        "Neuroblastoma",
        "Wilms Tumor",
        "Hepatic Tumor",
        "Germ Cell Tumor",
        "Desmoid Tumor"
      ],
      "interventions": [
        {
          "name": "Magnetic Resonance High Intensity Focused Ultrasound",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "AeRang Kim",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "Up to 30 Years"
      },
      "enrollment_count": 7,
      "start_date": "2014-04",
      "completion_date": "2024-11-24",
      "has_results": false,
      "last_update_posted_date": "2025-01-01",
      "last_synced_at": "2026-10-31T18:26:15.508Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02076906"
    },
    {
      "nct_id": "NCT02499952",
      "title": "Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Germ Cell Neoplasms",
        "Testicular Neoplasms",
        "Non Seminomatous Germ Cell Tumors",
        "Mediastinal Neoplasms",
        "Genital Neoplasms, Male",
        "Genital Neoplasms, Female",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nasser Hanna, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2016-01",
      "completion_date": "2017-01-13",
      "has_results": true,
      "last_update_posted_date": "2022-07-11",
      "last_synced_at": "2026-10-31T18:26:15.508Z",
      "location_count": 2,
      "location_summary": "Indianapolis, Indiana • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02499952"
    },
    {
      "nct_id": "NCT00591058",
      "title": "Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Glioma",
        "Glioblastoma Multiforme",
        "GBM",
        "Astrocytoma",
        "Oligodendroglioma"
      ],
      "interventions": [
        {
          "name": "TM-601",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TransMolecular",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2008-02",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2009-07-17",
      "last_synced_at": "2026-10-31T18:26:15.508Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00591058"
    }
  ]
}